A placebo-controlled trial of memantine for cocaine dependence with high-value voucher incentives during a pre-randomization lead-in period

Drug and Alcohol Dependence

Volumn 111, Issue 1-2, 2010, Pages 97-104

  Bisaga, Adam ^a   Aharonovich, Efrat ^a   Cheng, Wendy Y ^a   Levin, Frances R ^a   Mariani, John J ^a   Raby, Wilfrid N ^a   Nunes, Edward V ^a  

^a Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

Author keywords

Cocaine dependence; High value contingency reinforcement; NMDA receptors; Pharmacotherapy trials; Placebo lead in

Indexed keywords

MEMANTINE; PLACEBO;

ADULT; ANXIETY; ARTICLE; BACKACHE; CHILL; CLINICAL TRIAL; COCAINE DEPENDENCE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REINFORCEMENT; RELAPSE; REWARD; SIDE EFFECT; SINGLE BLIND PROCEDURE; TREATMENT DURATION; URINE LEVEL; WITHDRAWAL SYNDROME;

ADULT; BEHAVIOR THERAPY; CLINICAL TRIALS AS TOPIC; COCAINE-RELATED DISORDERS; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MEMANTINE; MIDDLE AGED; SEX FACTORS; SINGLE-BLIND METHOD; SUBSTANCE ABUSE DETECTION; TREATMENT OUTCOME;

EID: 77956189893     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2010.04.006     Document Type: Article

References (53)

1. Alterman A.I., Kampman K., Boardman C.R., Cacciola J.S., Rutherford M.J., McKay J.R., Maany I. A cocaine-positive baseline urine predicts outpatient treatment attrition and failure to attain initial abstinence. Drug Alcohol Depend. 1997, 46:79-85.
2. Anderson A.L., Reid M.S., Li S.H., Holmes T., Shemanski L., Slee A., Smith E.V., Kahn R., Chiang N., Vocci F., Ciraulo D., Dackis C., Roache J.D., Salloum I.M., Somoza E., Urschel H.C., Elkashef A.M. Modafinil for the treatment of cocaine dependence. Drug Alcohol Depend. 2009, 104:133-139.
3. Bespalov A.Y., Dravolina O.A., Zvartau E.E., Beardsley P.M., Balster R.L. Effects of NMDA receptor antagonists on cocaine-conditioned motor activity in rats. Eur. J. Pharmacol. 2000, 390:303-311.
4. Bespalov A.Y., Zvartau E.E., Balster R.L., Beardsley P.M. Effects of N-methyl-d-aspartate receptor antagonists on reinstatement of cocaine-seeking behavior by priming injections of cocaine or exposures to cocaine-associated cues in rats. Behav. Pharmacol. 2000, 11:37-44.
5. Bisaga A., Aharonovich E., Garawi F., Levin F.R., Rubin E., Raby W.N., Nunes E.V. A randomized placebo-controlled trial of gabapentin for cocaine dependence. Drug Alcohol Depend. 2006, 81:267-274.
6. Bisaga A., Aharonovich E., Garawi F., Levin F.R., Rubin E., Raby W.N., Vosburg S.K., Nunes E.V. Utility of lead-in period in cocaine dependence pharmacotherapy trials. Drug Alcohol Depend. 2005, 77:7-11.
7. Bisaga A., Comer S.D., Ward A.S., Popik P., Kleber H.D., Fischman M.W. The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans. Psychopharmacology 2001, 157:1-10.
8. Blokhina E.A., Kashkin V.A., Zvartau E.E., Danysz W., Bespalov A.Y. Effects of nicotinic and NMDA receptor channel blockers on intravenous cocaine and nicotine self-administration in mice. Eur. Neuropsychopharmacol. 2005, 15:219-225.
9. Carroll K.M. A Cognitive-Behavioral Approach: Treating Cocaine Addiction 1998, National Institute on Drug Abuse, Rockville, MD.
10. Collins E.D., Vosburg S.K., Ward A.S., Haney M., Foltin R.W. Memantine increases cardiovascular but not behavioral effects of cocaine in methadone-maintained humans. Pharmacol. Biochem. Behav. 2006, 83:47-55.
11. Collins E.D., Vosburg S.K., Ward A.S., Haney M., Foltin R.W. The effects of acute pretreatment with high-dose memantine on the cardiovascular and behavioral effects of cocaine in humans. Exp. Clin. Psychopharmacol. 2007, 15:228-237.
12. Collins E.D., Ward A.S., McDowell D.M., Foltin R.W., Fischman M.W. The effects of memantine on the subjective, reinforcing and cardiovascular effects of cocaine in humans. Behav. Pharmacol. 1998, 9:587-598.
13. Cornish J.L., Duffy P., Kalivas P.W. A role for nucleus accumbens glutamate transmission in the relapse to cocaine-seeking behavior. Neuroscience 1999, 93:1359-1367.
14. Covey L.S., Glassman A.H., Stetner F., Rivelli S., Stage K. A randomized trial of sertraline as a cessation aid for smokers with a history of major depression. Am. J. Psychiatry 2002, 159:1731-1737.
15. Crits-Christoph P., Siqueland L., Blaine J., Frank A., Luborsky L., Onken L.S., Muenz L.R., Thase M.E., Weiss R.D., Gastfriend D.R., Woody G.E., Barber J.P., Butler S.F., Daley D., Salloum I., Bishop S., Najavits L.M., Lis J., Mercer D., Griffin M.L., Moras K., Beck A.T. Psychosocial treatments for cocaine dependence: National Institute on Drug Abuse Collaborative Cocaine Treatment Study. Arch. Gen. Psychiatry 1999, 56:493-502.
16. Danysz W., Parsons C.G., Kornhuber J., Schmidt W.J., Quack G. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents--preclinical studies. Neurosci. Biobehav. Rev. 1997, 21:455-468.
17. Ehrman R.N., Robbins S.J., Cornish J.W. Results of a baseline urine test predict levels of cocaine use during treatment. Drug Alcohol Depend. 2001, 62:1-7.
18. Elkashef A.M., Rawson R.A., Anderson A.L., Li S.H., Holmes T., Smith E.V., Chiang N., Kahn R., Vocci F., Ling W., Pearce V.J., McCann M., Campbell J., Gorodetzky C., Haning W., Carlton B., Mawhinney J., Weis D. Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology 2008, 33:1162-1170.
19. Everitt B.J., Wolf M.E. Psychomotor stimulant addiction: a neural systems perspective. J. Neurosci. 2002, 22:3312-3320.
20. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I disorders - patient edition (SCID-I/P, Version 2.0). 1995, Biometrics Research Department, New York State Psychiatric Institute, New York, NY.
21. Gass J.T., Olive M.F. Glutamatergic substrates of drug addiction and alcoholism. Biochem. Pharmacol. 2008, 75:218-265.
22. Grabowski J., Rhoades H., Schmitz J., Stotts A., Daruzska L.A., Creson D., Moeller F.G. Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. J. Clin. Psychopharmacol. 2001, 21:522-526.
23. Haney M. Self-administration of cocaine, cannabis and heroin in the human laboratory: benefits and pitfalls. Addict. Biol. 2009, 14:9-21.
24. Hayes R.J., Vorel S.R., Spector J., Liu X., Gardner E.L. Electrical and chemical stimulation of the basolateral complex of the amygdala reinstates cocaine-seeking behavior in the rat. Psychopharmacology 2003, 168:75-83.
25. Higgins S.T., Budney A.J., Bickel W.K., Foerg F.E., Donham R., Badger G.J. Incentives improve outcome in outpatient behavioral treatment of cocaine dependence. Arch. Gen. Psychiatry 1994, 51:568-576.
26. Hotsenpiller G., Giorgetti M., Wolf M.E. Alterations in behaviour and glutamate transmission following presentation of stimuli previously associated with cocaine exposure. Eur. J. Neurosci. 2001, 14:1843-1855.
27. Hyytia P., Backstrom P., Liljequist S. Site-specific NMDA receptor antagonists produce differential effects on cocaine self-administration in rats. Eur. J. Pharmacol. 1999, 378:9-16.
28. Kalivas P.W., O'Brien C. Drug addiction as a pathology of staged neuroplasticity. Neuropsychopharmacology 2008, 33:166-180.
29. Kalivas P.W., Volkow N.D. The neural basis of addiction: a pathology of motivation and choice. Am. J. Psychiatry 2005, 162:1403-1413.
30. Kampman K.M., Volpicelli J.R., Mulvaney F., Rukstalis M., Alterman A.I., Pettinati H., Weinrieb R.M., O'Brien C.P. Cocaine withdrawal severity and urine toxicology results from treatment entry predict outcome in medication trials for cocaine dependence. Addict. Behav. 2002, 27:251-260.
31. Karila L., Gorelick D., Weinstein A., Noble F., Benyamina A., Coscas S., Blecha L., Lowenstein W., Martinot J.L., Reynaud M., Lepine J.P. New treatments for cocaine dependence: a focused review. Int. J. Neuropsychopharmacol. 2008, 11:425-438.
32. Kosten T., Oliveto A., Feingold A., Poling J., Sevarino K., McCance-Katz E., Stine S., Gonzalez G., Gonsai K. Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. Drug Alcohol Depend. 2003, 70:315-325.
33. Kotlinska J., Biala G. Memantine and ACPC affect conditioned place preference induced by cocaine in rats. Pol. J. Pharmacol. 2000, 52:179-185.
34. Krupitsky E.M., Neznanova O., Masalov D., Burakov A.M., Didenko T., Romanova T., Tsoy M., Bespalov A., Slavina T.Y., Grinenko A.A., Petrakis I.L., Pittman B., Gueorguieva R., Zvartau E.E., Krystal J.H. Effect of memantine on cue-induced alcohol craving in recovering alcohol-dependent patients. Am. J. Psychiatry 2007, 164:519-523.
35. Maldonado C., Rodriguez-Arias M., Castillo A., Aguilar M.A., Minarro J. Effect of memantine and CNQX in the acquisition, expression and reinstatement of cocaine-induced conditioned place preference. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:932-939.
36. Martinez D., Narendran R., Foltin R.W., Slifstein M., Hwang D.R., Broft A., Huang Y., Cooper T.B., Fischman M.W., Kleber H.D., Laruelle M. Amphetamine-induced dopamine release: markedly blunted in cocaine dependence and predictive of the choice to self-administer cocaine. Am. J. Psychiatry 2007, 164:622-629.
37. Miller, W.R., Zweben, A., DiClemente, C.C., Rychtarik, R.G., 1992. Motivational Enhancement Therapy Manual, DHHS Publication No. (ADM) 92-1894.
38. Moeller F.G., Schmitz J.M., Steinberg J.L., Green C.M., Reist C., Lai L.Y., Swann A.C., Grabowski J. Citalopram combined with behavioral therapy reduces cocaine use: a double-blind, placebo-controlled trial. Am. J. Drug Alcohol Abuse 2007, 33:367-378.
39. Mooney M.E., Sayre S.L., Green C., Rhoades H., Schmitz J.M. Comparing measures of medication taking in a pharmacotherapy trial for cocaine dependence. Addict. Dis. Treat. 2004, 3:165-173.
40. Newman J.L., Beardsley P.M. Effects of memantine, haloperidol, and cocaine on primary and conditioned reinforcement associated with cocaine in rhesus monkeys. Psychopharmacology 2006, 185:142-149.
41. Parsons C.G., Rammes G., Danysz W. Pharmacodynamics of memantine: an update. Curr. Neuropharmacol. 2008, 6:55-78.
42. Pettinati H.M., Kampman K.M., Lynch K.G., Suh J.J., Dackis C.A., Oslin D.W., O'Brien C.P. Gender differences with high-dose naltrexone in patients with co-occurring cocaine and alcohol dependence. J. Subst. Abuse Treat. 2008, 34:378-390.
43. Poling J., Oliveto A., Petry N., Sofuoglu M., Gonsai K., Gonzalez G., Martell B., Kosten T.R. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch. Gen. Psychiatry 2006, 63:219-228.
44. Preston K.L., Silverman K., Higgins S.T., Brooner R.K., Montoya I., Schuster C.R., Cone E.J. Cocaine use early in treatment predicts outcome in a behavioral treatment program. J. Consult. Clin. Psychol. 1998, 66:691-696.
45. Preston K.L., Silverman K., Schuster C.R., Cone E.J. Assessment of cocaine use with quantitative urinalysis and estimation of new uses. Addiction 1997, 92:717-727.
46. Preston K.L., Umbricht A., Wong C.J., Epstein D.H. Shaping cocaine abstinence by successive approximation. J. Consult. Clin. Psychol. 2001, 69:643-654.
47. Schmitz J.M., Mooney M.E., Moeller F.G., Stotts A.L., Green C., Grabowski J. Levodopa pharmacotherapy for cocaine dependence: choosing the optimal behavioral therapy platform. Drug Alcohol Depend. 2008, 94:142-150.
48. Shoptaw S., Heinzerling K.G., Rotheram-Fuller E., Steward T., Wang J., Swanson A.N., De La Garza R., Newton T., Ling W. Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2008, 96:222-232.
49. UNODC, 2009. United Nations Office on Drugs and Crime. World Drug Report 2009. United Nations, New York.
50. Vocci F., Ling W. Medications development: successes and challenges. Pharmacol. Ther. 2005, 108:94-108.
51. Vorel S.R., Liu X., Hayes R.J., Spector J.A., Gardner E.L. Relapse to cocaine-seeking after hippocampal theta burst stimulation. Science 2001, 292:1175-1178.
52. Wenk G.L., Danysz W., Mobley S.L. MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis. Eur. J. Pharmacol. 1995, 293:267-270.
53. Winhusen T., Somoza E., Sarid-Segal O., Goldsmith R.J., Harrer J.M., Coleman F.S., Kahn R., Osman S., Mezinskis J., Li S.H., Lewis D., Afshar M., Ciraulo D.A., Horn P., Montgomery M.A., Elkashef A. A double-blind, placebo-controlled trial of reserpine for the treatment of cocaine dependence. Drug Alcohol Depend. 2007, 91:205-212.